Evaluation of a gender synchronized family planning intervention for married couples in rural India: The CHARM2 cluster randomized control trial.
Cluster randomized controlled trial
Contraceptive use
Family planning
Gender equity
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
22
11
2021
revised:
27
01
2022
accepted:
16
02
2022
entrez:
11
3
2022
pubmed:
12
3
2022
medline:
12
3
2022
Statut:
epublish
Résumé
Despite calls for gender transformative family planning interventions to increase male engagement and female reproductive agency, there is limited research involving rigorous evaluation of the integration of these approaches. CHARM2 (counseling Husbands and wives to Achieve Reproductive Health and Marital Equity) builds upon a prior three-session male engagement intervention by integrating female-focused sessions emphasizing women's choice and agency (i.e., gender synchronization). We hypothesized that CHARM2 participants will be more likely to report marital contraceptive use and communication and women's contraceptive agency, and less likely to report unintended pregnancy, relative to participants in the control condition. We conducted a two-armed cluster randomized controlled trial evaluating the effects of CHARM2 on marital contraceptive use, communication, decision-making; women's contraceptive agency, and pregnancy among young married couples in rural Maharashtra, India (ClinicalTrials.gov #NCT03514914, complete). 40 geographic clusters, defined based on the catchment areas of subcenter health facilities (the most proximal level of community health care within India's public health system) were randomized to control ( 1201 couples were recruited between September 2018 and June 2019; 600 intervention and 601 control. All couples were included in outcome analyses. Full couple retention was 90·2% ( The CHARM2 intervention offers a scalable model to improve contraceptive use, communication, and agency and possibly decrease unplanned pregnancies for couples in rural India.
Sections du résumé
Background
UNASSIGNED
Despite calls for gender transformative family planning interventions to increase male engagement and female reproductive agency, there is limited research involving rigorous evaluation of the integration of these approaches. CHARM2 (counseling Husbands and wives to Achieve Reproductive Health and Marital Equity) builds upon a prior three-session male engagement intervention by integrating female-focused sessions emphasizing women's choice and agency (i.e., gender synchronization). We hypothesized that CHARM2 participants will be more likely to report marital contraceptive use and communication and women's contraceptive agency, and less likely to report unintended pregnancy, relative to participants in the control condition.
Methods
UNASSIGNED
We conducted a two-armed cluster randomized controlled trial evaluating the effects of CHARM2 on marital contraceptive use, communication, decision-making; women's contraceptive agency, and pregnancy among young married couples in rural Maharashtra, India (ClinicalTrials.gov #NCT03514914, complete). 40 geographic clusters, defined based on the catchment areas of subcenter health facilities (the most proximal level of community health care within India's public health system) were randomized to control (
Findings
UNASSIGNED
1201 couples were recruited between September 2018 and June 2019; 600 intervention and 601 control. All couples were included in outcome analyses. Full couple retention was 90·2% (
Interpretation
UNASSIGNED
The CHARM2 intervention offers a scalable model to improve contraceptive use, communication, and agency and possibly decrease unplanned pregnancies for couples in rural India.
Identifiants
pubmed: 35274093
doi: 10.1016/j.eclinm.2022.101334
pii: S2589-5370(22)00064-5
pmc: PMC8902598
doi:
Banques de données
ClinicalTrials.gov
['NCT03514914']
Types de publication
Journal Article
Langues
eng
Pagination
101334Subventions
Organisme : NICHD NIH HHS
ID : K12 HD001259
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD084453
Pays : United States
Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors have nothing to disclose.
Références
Lancet. 2019 Jun 22;393(10190):2522-2534
pubmed: 31155271
Reprod Health. 2018 Aug 28;15(1):144
pubmed: 30153846
Am J Prev Med. 2018 Nov;55(5):725-735
pubmed: 30342635
Stud Fam Plann. 2018 Mar;49(1):41-56
pubmed: 29441577
Int J Equity Health. 2021 Aug 19;20(1):186
pubmed: 34412647
Am J Prev Med. 2018 Nov;55(5):747-758
pubmed: 30342637
Reprod Health Matters. 2015 Nov;23(46):177-84
pubmed: 26719009
Stud Fam Plann. 2011 Jun;42(2):67-82
pubmed: 21834409
BMC Health Serv Res. 2020 Dec 11;20(1):1139
pubmed: 33308230
Lancet. 2019 Jun 22;393(10190):2535-2549
pubmed: 31155270
Sex Reprod Health Matters. 2020 Dec;28(1):1785378
pubmed: 32552622
Glob Health Sci Pract. 2021 Dec 21;9(4):948-963
pubmed: 34933989
Contraception. 2017 Sep;96(3):133-137
pubmed: 28645786
Gates Open Res. 2019 Apr 8;3:1114
pubmed: 31259315
J Health Commun. 2014;19 Suppl 1:122-41
pubmed: 25207450
Reprod Health. 2021 Jun 13;18(1):126
pubmed: 34120630
Contraception. 2016 Jul;94(1):58-67
pubmed: 26892333
Reprod Health. 2019 Jun 25;16(1):88
pubmed: 31238954
PLoS One. 2016 May 11;11(5):e0153190
pubmed: 27167981
Gates Open Res. 2021 May 21;5:85
pubmed: 34136752
Indian J Med Res. 2018 Dec;148(Suppl):S1-S9
pubmed: 30964076
Glob Health Sci Pract. 2018 Jun 29;6(2):330-344
pubmed: 29959273
Contraception. 2011 Mar;83(3):274-80
pubmed: 21310291
PLoS One. 2018 Sep 27;13(9):e0204088
pubmed: 30260991
Lancet. 2021 Jul 10;398(10295):99-101
pubmed: 33971154
Gender Issues. 2021;38(4):395-419
pubmed: 33132690